This review outlines the mechanisms of systemic inflammation during cardiopulmonary bypass and highlights the potential of anti-inflammatory strategies to reduce organ dysfunction.
Answers are grounded in this paper and cite their sources.
Anti-inflammatory strategies may reduce CPB-related organ dysfunction; leaves open optimal targets and efficacy in prospective trials.
The purpose of inflammation is to combat various agents that may injure the tissues. Conditions such as CPB can often cause systemic inflammation and dysfunction of major organs. Pulmonary, renal, myocardial and intestinal function may suffer various degrees of impairment during and after cardiac surgery. Although changes in major organs usually remain clinically insignificant, severe organ failure is not uncommon. The process of systemic inflammation proceeds through activation of serum proteins, activation of leucocytes and endothelial cells, secretion of cytokines, leucocyte-endothelial cell interaction, leucocyte extravasation and tissue damage. Several anti-inflammatory strategies have already been used, some of which have given promising results pertaining to further reduction in the rate of the inflammation-related complications in cardiac surgical patients.
No takes yet. Share an insight, caveat, or question.
George Asimakopoulos (1999) conducted a review in Systemic inflammation and organ dysfunction. Cardiopulmonary bypass (CPB) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: